Navigation Links
New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers
Date:6/16/2008

Potential therapy could be the next generation of treatments, researchers say

MONDAY, June 16 (HealthDay News) -- Researchers have identified a new group of compounds that might one day be added to the armamentarium of therapies designed to fight estrogen-fueled breast cancer.

"This is a potential new approach to treating hormonally sensitive tumors," said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. "If it proves to work with a lot of further research, then it does have potential as an important part of cancer research."

The study, by researchers from the University of North Carolina, Chapel Hill, the University of Colorado Health Sciences Center, Denver, and the University of Illinois, Urbana-Champaign, was presented Monday at the annual meeting of the Endocrine Society, in San Francisco.

The molecule, called TPBM, and related drugs may have a role in treating patients who have become resistant to other hormone-based therapies, such as tamoxifen.

"We have a large number of people who have estrogen receptor-positive breast cancer who respond wonderfully to hormone therapy. But, sometimes, after one or two years, the hormone therapy stops working," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "[Then] we'll switch to something else. That works for about a year before the cancer progresses. So what is it that's happening in those cancer cells that they become resistant? Perhaps there is another mechanism in which we can try to keep cells in response, and this would perhaps be one of them."

Some two-thirds of all breast cancers are estrogen receptor-positive and therefore respond to hormonal treatments such as tamoxifen or the newer aromatase inhibitors.

Tamoxifen blocks estrogen receptors on breast cancer cells, while aromatase inhibitors interfere with the body's ability to produce estrogen.

But almost all cancers in this category eventually become resistant to tamoxifen and, in some cases, tamoxifen may even turn the tables and start acting like estrogen, thereby fueling tumor growth.

Through extensive laboratory testing, the study authors identified a group of compounds related to TPBM that interfered with estrogen's effect on breast cancer cells via a different pathway. The molecules work by affecting the way estrogen receptors interact with a woman's DNA, the researchers said.

TPBM has the advantage of being "highly specific" and therefore much less likely to have any unwanted effects on other cells. It also works against tamoxifen when tamoxifen starts fueling tumor growth, the researchers said.

"As we look forward with all of our research and our capabilities, we'll hopefully continue to discover new ways to exploit hormone sensitivity," Lichtenfeld said. "This may be the next pathway, although we can't say that for sure... Hormonal approaches to breast cancer continue to add, literally, years to lives."

More information

For more on treating breast cancer, visit the National Cancer Institute.



SOURCES: Jay Brooks, M.D., chairman of hematology/oncology, Ochsner Health Service, Baton Rouge, La.; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; June 16, 2008, presentation, The Endrocine Society annual meeting, San Francisco


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New class of RNA molecules may be important in human cancer
2. Molecule Promising Against Huntingtons Disease
3. Free Access to Literature Data on Chagas Disease Offered Online: Collaborative Drug Discovery, Inc. provides Neglected Disease researchers with archive mine and collaborate access to small molecule bioactivity SAR data on parasitic disease
4. Vulnerability to Stress Linked to Brain Molecule
5. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
6. Study Describes Molecules That Control Blood Pressure
7. Researchers identify molecules with interesting anti-clotting properties
8. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
9. St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
10. Major Advance in the Observation of DNA Molecules
11. Molecules can block breast cancers ability to spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , ... recently partnered with Heart City Health Center to improve access to ... Heart City Health Center has provided the Elkhart community with access to high ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize critical ... leave patients with dental emergencies at risk of losing a tooth or their smiles. ... , Common dental emergencies include:, , Avulsed or knocked-out ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Ongoing news of ... Life Care Association™ (ALCA) to conduct a survey that takes a closer look at ... today illustrates the prevalence and causes of TBI among the aging population, and identifies ...
(Date:2/10/2016)... , ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: ... report results for the fourth quarter and full year ended December 31, 2015 on ... conference call and webcast for the investment community following the release at 4:30 PM ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... MOUNTAIN VIEW, Calif. , Feb. 10, ... result of a synergistic confluence of various ... unique value propositions, previously unavailable. These opportunities ... convergence and convergence, in turn, drives the ... Today,s entrepreneurial scenario is characterized by technology ...
(Date:2/10/2016)... Jersey and OR AKIVA, Israel ... Regentis Biomaterials Ltd., a leader in the ... Series D investment round on February 5, 2016. The ... Group ("Haisco"), a leading Chinese pharmaceutical manufacturer, and ... SCP Vitalife Partners, Generali Financial Holdings and both the ...
(Date:2/10/2016)... ALSP, Inc. announced that it has appointed Col.(Retired) Dallas ... preparation for its move into clinical trials with its lead ... are pleased to welcome Dallas Hack onto the ... of such practical knowledge and far-reaching experience in Traumatic Brain ... broad experience and success as a clinician and researcher in ...
Breaking Medicine Technology: